178 related articles for article (PubMed ID: 36323067)
1. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease.
Bay P; de Chambrun MP; Rothstein V; Mahevas M; De Prost N; Roux A; Zuber B; Biet DI; Hervier B; Tazi A; Mouthon L; Mekinian A; Deligny C; Borie R; Meurice JC; Meyer A; Priou P; Savale L; De Saint Martin L; Gallay L; Cottin V; Blanchard E; Brillet PY; Khafagy P; Benveniste O; Nunes H; Allenbach Y; Uzunhan Y
J Autoimmun; 2022 Dec; 133():102941. PubMed ID: 36323067
[TBL] [Abstract][Full Text] [Related]
2. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
Front Immunol; 2022; 13():845988. PubMed ID: 35320936
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
Abe Y; Kusaoi M; Tada K; Yamaji K; Tamura N
Rheumatology (Oxford); 2020 Apr; 59(4):767-771. PubMed ID: 31504956
[TBL] [Abstract][Full Text] [Related]
4. Early Initiation of Plasma Exchange Therapy for Anti-MDA5
Sasaki N; Nakagome Y; Kojima A; Shimura K; Ishii A; Sugiyama M; Izumi Y; Hirano K; Kurabayashi T; Hosono Y; Yamada C; Sato S
Intern Med; 2024 Jan; 63(2):213-219. PubMed ID: 37225493
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
[TBL] [Abstract][Full Text] [Related]
6. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
Wang L; Lv C; You H; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Liu J; Wang F; Zhang M; Tan W
Front Immunol; 2024; 15():1286973. PubMed ID: 38361940
[TBL] [Abstract][Full Text] [Related]
7. Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
Li M; Zhao X; Liu B; Zhao Y; Li X; Ma Z; Yang Q
Front Immunol; 2023; 14():1209282. PubMed ID: 37691917
[TBL] [Abstract][Full Text] [Related]
8. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
9. [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury].
Zhang PL; Yang HX; Zhang LN; Ge YP; Peng QL; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1055-1060. PubMed ID: 34916681
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
[TBL] [Abstract][Full Text] [Related]
11. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.
Shirakashi M; Nakashima R; Tsuji H; Tanizawa K; Handa T; Hosono Y; Akizuki S; Murakami K; Hashimoto M; Yoshifuji H; Ohmura K; Mimori T
Rheumatology (Oxford); 2020 Nov; 59(11):3284-3292. PubMed ID: 32276271
[TBL] [Abstract][Full Text] [Related]
13. Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature.
Lian QY; Chen A; Zhang JH; Xu X; Huang DX; Luo Q; He JX; Ju CR
Clin Rheumatol; 2023 Mar; 42(3):941-947. PubMed ID: 36441397
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
He C; Li W; Xie Q; Yin G
Front Immunol; 2021; 12():820163. PubMed ID: 35116041
[TBL] [Abstract][Full Text] [Related]
15. Liver Involvement is Associated with Higher Risk of Rapidly Progressive Interstitial Lung Disease and Mortality in Anti-Melanoma Differentiation-Associated Gene 5 Antibody- Positive Dermatomyositis.
Yang X; Cui X; Yang X; Ren B; Cheng X; Zhao X; Liu S; Tian T; Zhao H; Qu L; Li X
J Inflamm Res; 2024; 17():3101-3113. PubMed ID: 38774443
[TBL] [Abstract][Full Text] [Related]
16. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
Ge Y; Li S; Tian X; He L; Lu X; Wang G
Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
[TBL] [Abstract][Full Text] [Related]
17. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
Sasaki N; Ishii A; Kurabayashi T; Sugiyama M; Izumi Y; Nakagome Y; Hirano K; Sasaki S; Kondo Y; Nogi S; Nishikawa A; Hosono Y; Yamada C; Sato S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):87-94. PubMed ID: 33048020
[TBL] [Abstract][Full Text] [Related]
18. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
19. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
20. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
